Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $44.00 Consensus Target Price from Brokerages

Posted by on Jul 28th, 2026

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $44.00.

Several equities analysts have commented on ASMB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Monday, June 15th. Guggenheim reissued a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th.

View Our Latest Research Report on Assembly Biosciences

Hedge Funds Weigh In On Assembly Biosciences

Several large investors have recently made changes to their positions in the business. Informed Momentum Co LLC grew its stake in shares of Assembly Biosciences by 1.6% in the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock worth $1,004,000 after buying an additional 451 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in Assembly Biosciences by 4.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 800 shares during the last quarter. Geode Capital Management LLC raised its stake in Assembly Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after buying an additional 1,212 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Assembly Biosciences by 4.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after acquiring an additional 1,634 shares in the last quarter. Finally, Palumbo Wealth Management LLC boosted its holdings in Assembly Biosciences by 7.2% in the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after acquiring an additional 2,507 shares in the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Stock Up 1.4%

ASMB opened at $25.91 on Tuesday. The stock has a market cap of $411.71 million, a PE ratio of -235.52 and a beta of 1.08. The business has a 50 day moving average of $25.95 and a 200-day moving average of $27.64. Assembly Biosciences has a 52 week low of $16.90 and a 52 week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.11. The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. Equities analysts anticipate that Assembly Biosciences will post 1.9 EPS for the current year.

Assembly Biosciences Company Profile

(Get Free Report)

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

Featured Stories

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.